findmyKOL
Clinical trialNCT06648772RecruitingPhase 3Interventional

Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

SponsorHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Enrollment190Plaque Psoriasis
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Beijing Children'S Hospital, Capital Medical University

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • People'S Hospital of Peking University

    Beijing, China

  • Children'S Hospital of Hunan Province

    Changsha, China

  • the Second Xiangya Hospital of Central South University

    Changsha, China

  • Affiliated Hospital of Chengde Medical College

    Chengde, China

  • Sichuan Provincial People'S Hospital

    Chengdu, China

  • the Second People'S Hospital of Chengdu

    Chengdu, China

  • Affiliated Hospital of Chongqing Three Gorges Medical College

    Chongqing, China

  • the Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • the Sixth People'S Hospital of Dongguan

    Dongguan, China

  • Enshi Tujia and Miao Autonomous Prefecture Central Hospital

    Enshi, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, China

  • Hainan Fifth People'S Hospital

    Haikou, China

  • the First People'S Hospital of Hangzhou

    Hangzhou, China

  • Zhejiang Provincial People'S Hospital

    Hangzhou, China

  • the Second Affiliated Hospital of Harbin Medical University

    Harbin, China

  • Ji'Nan Central Hospital

    Ji'nan, China

  • the First Hospital of Jilin University

    Jilin City, China

  • the Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Jinhua, China

  • the Second Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • Sanmenxia Central Hospital

    Sanmenxia, China

  • Shanghai Skin Disease Hospital

    Shanghai, China

  • the Second Affiliated Hospital of South Anhui Medical College

    Wuhu, China

  • the First Affiliated Hospital of Xi'An Jiaotong University

    Xi'an, China

  • the Second Affiliated Hospital of Xi'An Jiaotong University

    Xi'an, China

  • the First People'S Hospital of Yancheng

    Yancheng, China

  • Zhengzhou Central Hospital

    Zhengzhou, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Nov 2024
Primary completion
13 Oct 2025
Completion
15 Oct 2025
Last update posted
6 Jul 2026
Registered enrollment
190
Registry id
NCT06648772

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.